SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chip

Chip is experiencing intense volatility and trading volume as investors debate its long-term potential as an AI-focused infrastructure token versus concerns regarding insiders and potential pump-and-dump activity. The community is actively discussing the impact of its rapid listing on major brokerages and closely monitoring price action for signs of a squeeze.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic remains a subject of intense community debate, with proponents pointing to consistent monthly token burns by Binance and ecosystem developments like the LUNCVERSE as catalysts for a potential long-term recovery. Meanwhile, skeptics continue to label the asset a failed project, highlighting ongoing volatility and lingering sentiment from the original ecosystem collapse as key reasons for caution.

Airgain, Inc. provides embedded antenna products, integration support and test services. The firm works in partnership with the entire ecosystem, including carriers, chipset suppliers, OEMs, and ODMs. Its products include embedded, external and carrier-class antennas. The company offers custom antenna design and performance validation services. Its antennas are deployed in carrier, fleet, enterprise, residential, private, government, and public safety wireless networks and systems, including set-top boxes, access points, routers, modems, gateways, media adapters, and asset tracking devices. The company was founded on March 20,1995 and is headquartered in San Diego, CA.

Airgain Inc

Airgain Inc is trending following news of a multi-million dollar design win with a major U.S. utility to deploy its wireless connectivity technology across its fleet. Investors are actively discussing the potential impact of this contract and whether the company can maintain this momentum to drive long-term revenue growth.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is trending as traders discuss a potential short squeeze and high-volume price surge, with many speculating on the impact of upcoming governance proposals and Solana ecosystem growth. Community sentiment remains divided between those aggressively accumulating the asset for its perceived low-float upside and skeptics who are monitoring for signs of profit-taking or volatility.

FLOKI is a community-driven, multi-chain utility token that powers a broad ecosystem including decentralized gaming, finance, and educational platforms. Originally evolving from a meme-based asset, the project now focuses on a utility-driven model centered around three pillars: community engagement, technical utility, and global charity work, balancing this ecosystem growth with social impact, such as building schools in developing nations like Ghana and Nigeria.  Key features include Valhalla, an NFT metaverse game where the token serves as the primary currency for capturing creatures and upgrading characters. The ecosystem also features the FlokiFi Locker for securing digital assets and the University of FLOKI for web3 education,with real-world integration facilitated through a prepaid debit card for everyday purchases at global stores. Staking FLOKI allows users to earn rewards in a sister token.  The project is led by a group of core advisors known by pseudonyms such as Sabre and B (The Viking) and is officially backed by DWF Labs, a major digital asset investment firm and market maker. While a small tax on decentralized trades helps fund development, value moves through the system as users utilize the token to pay for in-game items, access asset-locking services, or purchase merchandise.

Floki Token

Floki is currently generating significant community buzz as investors focus on its expansion into institutional finance through ETP listings and ongoing ecosystem developments like the Valhalla metaverse. Supporters are actively discussing the token's potential for a broader meme sector rally, often highlighting its historical trend patterns and anticipation of future liquidity cycles.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently sparking intense debate within the community, with many investors actively accumulating during the current price consolidation while others express frustration over the lack of major project milestones and price momentum. Sentiment remains deeply polarized between those maintaining long-term conviction in the project's utility and those concerned by the significant lag in performance compared to broader market trends.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. Its products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits and embedded graphics. The company was founded in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

Silicon Motion is seeing significant volatility and investor interest following news that Chinese regulators have conditionally cleared its long-standing merger deal with MaxLinear. The community is actively debating the implications of the acquisition's path forward, with traders closely monitoring the spread between the current price and the deal's implied value as they navigate heightened volume and regulatory uncertainty.

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Lantheus Holdings is currently trending as investors focus on its strategic expansion into radiopharmaceuticals, bolstered by its significant equity stake in Radiopharm Theranostics and recent portfolio acquisitions. The community is actively discussing the potential for a larger buyout of smaller radiopharma players as Lantheus aims to consolidate its leadership in cancer diagnostics and therapeutics.

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Durham, NC.

Simulations Plus Inc.

Simulations Plus is trending as investors monitor its recent fiscal performance and strategic focus on integrating AI into drug development processes. The community is actively discussing the company's role as a niche healthcare AI player and evaluating the balance between its long-term growth potential in biosimulation and broader industry market volatility.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is gaining significant attention following the adoption of a new ve-style tokenomics system aimed at enhancing DeFi liquidity and accrual across the network. Community sentiment remains polarized as participants monitor recent volatility and technical consolidation while weighing the potential impact of future ecosystem developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?

5 Dividend ETFs Beating the S&P 500 This Year

Five dividend ETFs -- DFJ, SCHD, FDL, HDV and EYLD -- have outpaced SPY in 2026 as investors rotate toward quality income plays.

<ul class="summary-bullets"><li>Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes.</li><li>The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.</li><li>For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data.</li></ul>Pfizer Inc. (PFE) stock was in the spotlight on Tuesday after the company reported positive updates from a study testing weight loss treatment and a better-than expected fourth quarter print.However, <a href="https://stocktwits.com/symbol/PFE">PFE shares</a> were down 2% in pre-market trading on Tuesday as investors appeared to remain cautious about growth risks and the long road ahead for its GLP-1 pipeline.&nbsp;<h2 class="st-heading-2">Positive Topline Results For Weight Loss Treatment&nbsp;</h2>Pfizer reported positive topline results from its Phase 2b VESPER-3 study evaluating PF’3944, an ultra-long-acting injectable GLP-1 receptor agonist, in adults with obesity or overweight without type 2 diabetes.The trial aimed to determine whether patients could maintain weight loss while switching from weekly to once-monthly injections and whether the treatment would retain a favorable safety profile.The study met its primary endpoint, delivering statistically significant weight reduction across all tested doses. Participants achieved up to 12.3% mean placebo-adjusted weight loss at week 28. PF’3944 was generally well tolerated, with mostly mild to moderate gastrointestinal side effects and limited treatment discontinuations. The safety profile remained consistent with the broader GLP-1 drug class.“Based on the monthly dosing efficacy and tolerability demonstrated in this trial, we remain confident in our plan to include a higher 9.6 mg monthly maintenance dose of PF’3944 in Phase 3,” said Jim List, Chief Internal Medicine Officer.Following its acquisition of Metsera and a global licensing deal with YaoPharma, Pfizer said it is accelerating its obesity treatment pipeline. The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.<h2 class="st-heading-2">Q4 Earnings Snapshot</h2>Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted earnings between $2.80 and $3 per share. The company said the outlook includes roughly $5 billion in expected COVID-19 product sales and a projected $1.5 billion year-over-year revenue hit from certain products losing exclusivity.The company posted a 2% decline in FY2025 revenue at $62.6 billion with adjusted earnings of $3.22 per share.For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data. It also posted a better-than-expected EPS of $0.66.<h2 class="st-heading-2">What Did Stocktwits Users Say?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes. PFE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/PFE_jpg_91e98a5cdf.webp" alt="PFE.jpg" width="928" height="111"><figcaption>PFE's Sentiment Meter and Message Volumes in Pre-Market on Feb. 3, 2026 | Source: Stocktwits</figcaption></figure>One user expects multiple upcoming catalysts this year for the stock.<stembedurl>https://stocktwits.com/giuseppe8469/message/643776399</stembedurl>Another user highlighted key support and resistance levels.<stembedurl>https://stocktwits.com/Jas45z/message/643776263</stembedurl>The stock has gained around 1.5% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-pre-market-what-moving-average-indicates/cZbiqlvR4ln">SOFI Stock Hovers Around 200-DMA — A Make-or-Break Test Looms</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling?

Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion, while its FY2025 revenue came in at $62.6 billion.

Equity

<ul class="summary-bullets"><li>It expects full-year ongoing earnings per diluted share of approximately $7.00, which was lower than the analyst expectations of $7.21 per share.</li><li>The company said it expects debt reduction of approximately $400 million as it continues to review all options to reduce debt.</li><li>Its FY2025 sales of $15.5 billion, fell 6.5% compared to FY2024.</li></ul>Shares of Whirlpool slumped more than 8% on Thursday as weak fourth-quarter earnings and lower forecast for FY26 disappointed investors.&nbsp;The weak forecast prompted strong criticism from the retail traders on the performance of the company.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WHR trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One bearish user on Whirlpool's earnings said, “Disappointment again? That’s only like 20 quarters in a row”.&nbsp;<stembedurl>https://stocktwits.com/Siksika/message/643306159</stembedurl>Another user on Stocktwits predicted that “the dividend is going to get cut or eliminated. They don’t have the cash this year from operations to fund their dividend.”<stembedurl>https://stocktwits.com/freddycan/message/643262444</stembedurl><h2 class="st-heading-2">Weak Forecast</h2>The company said on a full year basis in 2026, it expects net sales of $15.3 - $15.6 billion; approximately 5% growth vs 2025 like-for-like.&nbsp;It expects full-year ongoing earnings per diluted share of approximately $7.00, which was lower than the expectations of $7.21 per share by analysts.&nbsp;The company said it expects debt reduction of approximately $400 million as it continues to review all options to reduce debt that align with its capital allocation priorities and maximize shareholder value.&nbsp;“Price/mix to favorably impact our EBIT margin as we continue to deliver new product innovation and realize the momentum of our 2025 launches,” it said in a statement.&nbsp;<h2 class="st-heading-2">Earnings Miss</h2>The company reported fourth quarter adjusted earnings per share of $1.10, which fell well short of Wall Street consensus of $1.52 per share, according to data from fiscal.ai.Its revenue of $4.1 billion also came below analysts’ expectations of $4.27 billion. Its FY2025 sales of $15.5 billion, fell 6.5% compared to FY2024.&nbsp;“With a challenging 2025 behind us, our confidence for 2026 is based on our recent successful product launches, reduced promotional intensity and a gradual recovery of the housing market,” said CEO Marc Bitzer.&nbsp; &nbsp;

Close-up of logo for appliance company Whirlpool on a clothes dryer in a domestic room, August 21, 2019. 

WHR Slips 7% — Why Is Retail Expecting Whirlpool To Eliminate Dividend?

Whirlpool reported fourth quarter adjusted earnings per share of $1.10, which fell well short of Wall Street consensus of $1.52 per share, according to data from fiscal.ai.

5 High-Dividend ETFs to Earn Current Income 

Market looks overheated? Earn stable income with high-dividend ETFs ??? FGD, FDL, IDV, SPYD and DIVO ??? as volatility boosts the appeal of yield.

6 Dividend ETFs Under $50 to Buy Now

Market volatility sparks income hunt -- dividend ETFs like SCHD, CGDV, SPYD, IDV, FDL & DIVO under $50 offer steady yields and value.

<ul class="summary-bullets"><li>Battery electric vehicle sales, however, took a sharp hit, decreasing by 24.8% to 4,709 units, likely due to the expiration of the federal tax credit of $7,500 on the purchase of new EVs in the U.S. on September 30.&nbsp;</li><li>The F-series truck continued to be the company’s best-seller in October with 67,930 units sold, marking a growth of 0.7% year-over-year.&nbsp;</li><li>The company’s SUV sales, however, fell 4.7% last month to 65,968 units.&nbsp; &nbsp;</li></ul>Ford Motor Co. (F) on Monday said that it delivered 175,584 vehicles in the U.S. in October, marking a growth of 1.6% from the corresponding period last year, thanks to continued demand for its F-series trucks.The growth was primarily driven by a 3.4% growth in sales of the company’s internal combustion engine vehicles.<h2 class="st-heading-2">Electric Vehicle Sales Dive</h2>Battery electric vehicle sales, however, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s205.q4cdn.com/882619693/files/doc_news/2025/Nov/03/Ford-U-S-October-2025-Sales-Release.pdf">took</a> a sharp hit, decreasing by 24.8% to 4,709 units, likely due to the expiration of the federal tax credit of $7,500 on the purchase of new EVs in the U.S. on September 30.While the company’s Mustang Mach-E sales dived 12.3% to 2,906 units, sales of its EV truck F-150 Lightning dropped 17.2% to 1,543 units. Sales of the company’s electric E-transit van, meanwhile, fell 76.1% to just 260 units.Last month, General Motors announced that it is canceling production of E-transit’s competitor, Brightdrop electric van, in Canada, citing slow development in the commercial electric van market.<h2 class="st-heading-2">F-Series Continues To Reign</h2>The F-series truck continued to be the company’s best-seller in October with 67,930 units sold, marking a growth of 0.7% year-over-year.The company’s SUV sales, however, fell 4.7% last month to 65,968 units, as sales of all of the company’s Lincoln brand SUVs fell, except the Navigator. The retirement of the Ford Edge SUV also weighed on the SUV sales numbers.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/F">F stock</a> is down by 1% at the time of writing. On Stocktwits, retail sentiment around F stock remained within the ‘bearish’ territory, while message volume decreased from ‘normal’ to ‘low’ levels.A Stocktwits user highlighted that November is typically a good month for autos.<stembedurl>https://stocktwits.com/ChumpMoney/message/634683037</stembedurl>F stock is up 31% this year and approximately 25% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-musks-1-trillion-pay-package-to-receive-overwhelming-approval/cL2NOFZR3zw">Gary Black Expects Musk’s $1T Pay Package To Receive ‘Overwhelming’ Approval But Warns Against Optimism On Tesla Robotaxi Expansion Plans</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Goldman Sachs reportedly upgraded the stock to ‘Buy’ from ‘Neutral’ and raised its price target to $13 from $12.

Ford Sales In US Rise 1.6% In October On Continued Truck Demand

The growth was primarily driven by a 3.4% growth in sales of the company’s internal combustion engine vehicles. 

The Zacks Analyst Blog Highlights Invesco QQQ Trust, Palantir, NVIDIA, Home Depot, S&P 500 Pure Value Invesco ETF and Morningstar Dividend Leaders ETF

Tech weakness pressures QQQ, Palantir and NVIDIA, while Home Depot, value ETFs and dividend funds attract investors amid sector rotation.

Time for a Sector Rotation Away from Tech? ETFs in Focus

Tech slump dragged QQQ lower as investors eye rotation into value ETFs like RPV, consumer staples ETFs like IYK, and dividend-focused ETFs like FDL.

First Trust Exchange-Traded Fund - First Trust Morningstar Dividend Leaders Index Fund

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

FDL
First Trust Exchange-Traded Fund III - First Trust Morningstar Dividend Leaders Index Fund

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FDL News

FDLFirst Trust Exchange-Traded Fund III - First Trust Morningstar Dividend Leaders Index Fund